BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study

Gautam Borthakur, Yishai Ofran, Martin S. Tallman, James Foran, Geoffrey L. Uy, John F. DiPersio, Margaret M. Showel, Avichai Shimoni, Arnon Nagler, Jacob M. Rowe, Jessica K. Altman, Michal Abraham, Amnon Peled, Stephen Shaw, Osnat Bohana-Kashtan, Ella Sorani, Yaron Pereg, Adam Foley-Comer, Galia Oberkovitz, Tzipi M. LustigIrit Glicko-Kabir, Arnon Aharon, Abi Vainstein-Haras, Shaul E. Kadosh, Emil Samara, Ahmed N. Al-Rawi, Naveen Pemmaraju, Carlos Bueso-Ramos, Jorge E. Cortes, Michael Andreeff

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Fingerprint Dive into the research topics of 'BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study'. Together they form a unique fingerprint.

Medicine & Life Sciences